Blood Thinners Before Cosmetic Surgery: Who Can Safely Pause Eliquis, Warfarin, or Plavix, Who Should Never Stop, Why Bridging Shots Usually Do More Harm Than Good, and the Stent Patients Who Should Simply Wait

The consultation goes smoothly until the medication list. The patient is 64, healthy enough to walk five miles a day, and wants a lower facelift and a neck lift. They also take apixaban, sold as Eliquis, because an episode of atrial fibrillation was found on a watch two years ago. The surgeon's reaction is the moment the patient learns that this pill is not a footnote. It is the single most important variable in whether the operation is reasonable, and the decision about it does not belong to the surgeon alone.

Blood thinners before cosmetic surgery sit at the intersection of two risks that pull in opposite directions. Leave the drug in place and the operation bleeds more, which in facelift surgery means a higher chance of a hematoma, the complication that already dominates the early recovery. Stop the drug and the condition it was prescribed for comes back into play: a stroke from atrial fibrillation, a recurrent clot in the leg or lungs, a clot on a mechanical heart valve, or a coronary stent that closes. In medically necessary surgery, that trade is accepted because the operation has to happen. In elective cosmetic surgery, there is always a third option, which is to wait or not operate at all.

This piece explains how the trade is actually managed: which drugs can be paused briefly and how, what the large trials on pausing and on bridging injections found, why the antiplatelet drugs used after a stent follow stricter rules, when stopping a thinner is the wrong call for smaller procedures, and how the restart is timed. It builds on the earlier pieces on supplements to stop before surgery, blood clots after plastic surgery, and age and cosmetic surgery, which mentioned prescription thinners only in passing.

Why the decision runs in both directions

The short answer: a prescription blood thinner exists to prevent a specific, often catastrophic event, so the question before cosmetic surgery is never just "how do we reduce bleeding" but "how much protection can this patient safely give up, for how long, for an operation they do not medically need," and that answer comes from the prescribing cardiologist or hematologist working with the surgeon.

It helps to separate the two families of drugs patients lump together as "blood thinners," because they work differently and are managed differently:

• Anticoagulants slow the clotting cascade. They include warfarin (Coumadin, Jantoven) and the direct oral anticoagulants, often called DOACs: apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). They are prescribed mainly for atrial fibrillation, for deep vein thrombosis or pulmonary embolism, and, in the case of warfarin, for mechanical heart valves.
• Antiplatelet drugs stop platelets from clumping. They include aspirin, clopidogrel (Plavix), prasugrel (Effient), and ticagrelor (Brilinta). They are prescribed mainly after a heart attack, a stroke, or the placement of a coronary stent, and aspirin is also taken, often without any prescription at all, by people who believe it protects the heart.

Every one of these raises surgical bleeding. But the risk of stopping each one depends entirely on why the patient takes it, and that is where the planning has to begin. Thrombosis specialists sort patients by the risk of a clot during a pause:

• Higher thrombotic risk includes a mechanical mitral valve or an older-design mechanical valve, a clot in a vein or the lungs within roughly the past three months, a recent stroke, atrial fibrillation with several stroke risk factors, and certain inherited clotting disorders.
• Lower thrombotic risk includes atrial fibrillation with few risk factors and a single clot that was provoked by a temporary cause, such as an injury, and treated more than a year ago.

The American College of Chest Physicians, whose guideline on perioperative management of antithrombotic therapy was updated in 2022, treats a venous clot within the previous three months as a reason to delay elective surgery whenever possible. For a cosmetic operation, "whenever possible" means always. The same logic applies to a recent stroke or heart attack. Nothing about a facelift or an abdominoplasty is improved by being done in the months when the underlying disease is most dangerous.

Then there is the operation's own bleeding risk. Liposuction, abdominoplasty, breast reduction, facelift, and neck lift all create large raw surfaces under skin flaps, where even a small amount of extra bleeding collects into a hematoma or seroma. In bleeding-risk terms they are high-risk procedures, closer to major general surgery than to a dental cleaning. That classification drives how long a thinner is held.

"

A blood thinner is prescribed to prevent a stroke, a clot, or a heart attack. Pausing it for a cosmetic operation means borrowing against that protection, and the person who decides how much can be borrowed should be the one who prescribed it.

"

The practical consequence is a rule worth repeating: the patient should never stop a prescription anticoagulant or antiplatelet drug on their own, and should be wary of any practice that tells them to without contacting the prescriber. A competent surgical office writes to the cardiologist or hematologist, describes the operation and its bleeding risk, and asks for a written plan. When the prescriber says the pause is unsafe, the honest response is to postpone or to choose a smaller procedure, not to look for a second opinion that says otherwise.

Eliquis, Xarelto, and warfarin: how a short pause is done, and why bridging fell out of favor

The short answer: the direct oral anticoagulants wear off quickly, so for a high-bleeding-risk operation they are typically held for about two days beforehand (longer for dabigatran when kidney function is reduced) and restarted two to three days afterward without any bridging injections, while warfarin is usually stopped about five days ahead, and a large randomized trial found that bridging with heparin shots in atrial fibrillation patients doubled major bleeding without preventing strokes.

The DOACs changed perioperative medicine because they leave the body fast. Their effect fades over a day or two in someone with normal kidney function, which means a short interruption leaves a short window of exposure. The question of exactly how short was answered most clearly by the PAUSE study, published in JAMA Internal Medicine in 2019. It followed more than 3,000 patients with atrial fibrillation taking apixaban, rivaroxaban, or dabigatran who needed surgery or a procedure, and used a simple standardized schedule:

• Low-bleeding-risk procedures: hold the drug one day before, restart one day after.
• High-bleeding-risk procedures: hold the drug two days before, restart two to three days after.
• Dabigatran with reduced kidney function: hold longer, because the kidneys clear it.
• No bridging injections for anyone.

With that schedule, rates of major bleeding and of stroke or other arterial clots at 30 days were low, with arterial clots well under one percent. The study did not include facelifts specifically, and nobody should treat its numbers as a promise for a particular cosmetic operation, but it gave surgeons and cardiologists a tested framework instead of guesswork. Most cosmetic body and face procedures fall in the high-bleeding-risk column.

Warfarin is slower in both directions. Its effect is measured by the INR, a blood test of how long blood takes to clot, and after the last dose it takes roughly five days for the INR to drift back toward normal. The usual plan is to stop it about five days before surgery and check the INR the day before or the morning of the operation; surgery proceeds only when the number is close to normal. After surgery warfarin is restarted, often within a day once bleeding is controlled, but it takes several days to become fully effective again. The total gap in protection is therefore longer with warfarin than with a DOAC, which is one reason the prescriber's view of the underlying risk matters more for warfarin patients.

For years, that gap was filled with bridging: injections of low molecular weight heparin, such as enoxaparin or dalteparin, given while warfarin was off, on the theory that the patient should never go unprotected. The BRIDGE trial, published in the New England Journal of Medicine in 2015, tested that theory in almost 1,900 patients with atrial fibrillation who were stopping warfarin for surgery. Half received bridging injections and half received placebo. Strokes and other arterial clots were rare and not reduced by bridging, while major bleeding was roughly two and a half times as common in the bridging group. For a cosmetic patient, that is the worst of both worlds: more blood under a flap, and no measurable gain in protection.

Bridging has not disappeared. It is still considered for the highest-risk patients, especially those with a mechanical mitral valve, an older mechanical valve design, or a very recent clot. But those are precisely the patients for whom an elective cosmetic operation is hardest to justify. A mechanical valve, notably, is managed with warfarin rather than a DOAC, because a randomized trial of dabigatran in mechanical valve patients was stopped early for excess clots and bleeding. A cosmetic surgeon who is comfortable bridging a mechanical valve patient through a facelift is taking a risk that most cardiologists would not endorse.

Two more points belong in this section because they are where real patients get hurt:

• The prescribed thinner is rarely the only one. Fish oil, vitamin E, ginkgo, garlic, and turmeric supplements, the over-the-counter painkillers in the ibuprofen family, and even SSRI antidepressants add their own effect on bleeding. A patient carefully pausing apixaban while still taking fish oil and naproxen has not really paused much.
• Kidney function changes the math. DOACs are cleared partly or mostly by the kidneys. A creatinine result from a year ago is not good enough; the pre-operative bloodwork for an anticoagulated patient should include a current one so the hold time can be calculated rather than assumed.

Aspirin, Plavix, and coronary stents: the patients who should simply wait

The short answer: daily aspirin taken without a clear medical reason can usually be stopped about seven to ten days before surgery, but antiplatelet therapy after a coronary stent is a different matter entirely, because stopping it early can cause the stent to clot shut, and cardiology guidelines advise delaying elective surgery for months after a stent rather than interrupting the drugs.

Aspirin is the thinner patients most often forget to mention, because many of them bought it themselves. Its effect on platelets is permanent for the life of each platelet, which is about a week to ten days, so stopping it a few days before surgery accomplishes little. When aspirin was started for "primary prevention," meaning the patient has never had a heart attack, stroke, or stent, the case for it has weakened considerably: in 2022 the U.S. Preventive Services Task Force recommended against starting low-dose aspirin for primary prevention in adults 60 and older, because the bleeding risk outweighed the benefit. A patient in that situation should still ask their physician before stopping, but the conversation is usually short, and in many cases the aspirin should not have been there in the first place.

Aspirin taken for "secondary prevention," after a heart attack, a stroke, bypass surgery, or a stent, is a different drug in practice, even though the pill is identical. Cardiologists often prefer to keep it going through surgery and accept the modest bleeding increase. That is a reasonable choice for an operation that must happen. For a cosmetic operation with large dissection, it is exactly the conversation in which the surgeon may decide that a smaller procedure, or none, is the safer recommendation.

Coronary stents raise the stakes further. After a stent is placed, patients take dual antiplatelet therapy: aspirin plus a second drug such as clopidogrel, prasugrel, or ticagrelor. The second drug keeps the stent from clotting while the artery lining heals over the metal. Interrupt it too early and the stent can thrombose, which typically presents as a heart attack and carries a high death rate. The American College of Cardiology and American Heart Association guidance on dual antiplatelet therapy advises that elective noncardiac surgery be delayed at least 30 days after a bare-metal stent and optimally at least six months after a drug-eluting stent, which is the type most patients now receive. Earlier surgery is contemplated only when the risk of further delay outweighs the risk of stent thrombosis, a description that does not fit any cosmetic operation.

When surgery does eventually proceed and the cardiologist agrees to pause the second drug, typical hold times are about five days for clopidogrel, about seven days for prasugrel, and three to five days for ticagrelor, usually with aspirin continued. Patients should hear those numbers as a description of what their cardiologist may decide, not as instructions.

When stopping is the wrong move: injectables, lasers, and small procedures

The short answer: for neurotoxin, filler, most lasers, and small skin procedures, the usual advice is to keep taking a prescribed blood thinner and accept more bruising, because the bleeding risk of those treatments is minor while the risk of a stroke or clot from stopping is not, though a few of them deserve extra caution.

Not every cosmetic treatment justifies interrupting a drug that prevents strokes. Botulinum toxin injections, filler, microneedling, and most energy-based skin treatments produce small, superficial bleeding that the body controls on its own even when anticoagulated. The predictable cost is bruising: more of it, larger, and longer-lasting. Patients can plan around that by scheduling well before a visible event, by accepting that a filler and toxin session may leave marks for a week or more, and by pausing the optional contributors, such as fish oil, vitamin E, and ibuprofen, with their physician's agreement. Remedies such as arnica have limited evidence behind them, as the piece on arnica and bromelain explains.

Dermatologic surgery offers the clearest precedent. For years the skin surgery literature, including studies of Mohs surgery for skin cancer, has favored continuing medically necessary anticoagulants and antiplatelet drugs for small excisions and reconstructions, because serious bleeding is uncommon and is managed locally, while reports of strokes and other clots after patients stopped their medication for minor skin procedures made the trade look poor. The same principle applies to small cosmetic excisions such as cyst and lipoma removal.

A few treatments sit in a gray zone and deserve a specific conversation:

• Deeper filler placement and cannula work. A large deep bruise or a small hematoma after deep cheek or temple filler is more likely on a thinner. That is not a reason to stop the drug, but it is a reason to choose an injector who uses careful technique and to avoid stacking many areas in one session.
• Small-volume liposuction under local anesthesia. Even "minor" liposuction, including the awake procedures marketed as lunch-hour treatments, involves tunneling through fat with cannulas. On a thinner it bleeds more, bruises far more, and can collect a hematoma. It belongs closer to the surgical category than the injectable one.
• Ablative laser resurfacing and deep chemical peels. Oozing from treated skin is greater on a thinner, and these treatments also carry their own healing considerations. The plan should be made with the prescriber, not improvised.

The underlying principle is proportion. The more tissue is dissected, and the more space exists under skin for blood to collect, the stronger the case for a planned pause. The more superficial the treatment, the stronger the case for leaving the protective drug alone.

The restart: timing it so neither a hematoma nor a clot wins

The short answer: blood thinners are generally restarted one to three days after surgery, later after operations with large flaps or a high bleeding risk, and the exact day should be agreed in advance among the surgeon, the anesthesiologist, and the prescriber, because restarting too early invites a hematoma and restarting too late leaves the patient unprotected during a period when the surgery itself raises clot risk.

The days after surgery are paradoxical for an anticoagulated patient. The operation raises the risk of bleeding into the surgical site, which is highest in the first day or two, and the earlier hematoma piece describes how most facelift hematomas declare themselves within the first 24 hours. At the same time, the operation itself raises the risk of a clot: surgery, anesthesia, reduced mobility, and long operating times are all on the list of factors that make up the Caprini score discussed in the earlier blood clots piece. A patient who already needed a thinner before surgery now has both of their risks elevated at once.

That is why the restart plan should be written down before the operation, not improvised at the first post-operative visit. Common elements include:

• A specific restart day and dose, reflecting the operation's bleeding risk. The PAUSE framework restarted DOACs two to three days after high-bleeding-risk procedures; the surgeon may ask for the later end of that range after a large flap operation.
• A decision about post-operative injections. Some patients who would otherwise receive short-course enoxaparin after body contouring will instead simply resume their usual anticoagulant. Doubling up, giving both, is a recipe for bleeding, and the plan should say clearly which one applies.
• Drains and garments as monitoring tools. Surgical drains let the team see whether output rises after the thinner restarts. A sudden jump in drain output, a new tense swelling, or a rapidly enlarging bruise on one side should prompt a same-day call.
• Avoiding combined marathons. Long, combined operations raise clot risk and bleeding risk at the same time. For an anticoagulated patient, splitting a mommy makeover or a body lift into stages is often the more conservative plan.
• No travel gamble. Flying home on day two after a body procedure while the thinner is still paused stacks the clot risks that the piece on flying after cosmetic surgery describes. It is also why anticoagulated patients are poorly suited to surgery abroad, where the surgeon has no relationship with the prescriber and no way to manage a complication after the patient leaves.

Patients should also know the warning signs on both sides of the trade. For bleeding: rapid one-sided swelling, tightness, increasing pain, bruising that spreads quickly, or blood soaking dressings. For clotting: calf pain or swelling, sudden shortness of breath, chest pain, or a fast heartbeat, and, for atrial fibrillation patients, the stroke signs of face drooping, arm weakness, or slurred speech. The first group means calling the surgeon now. The second group means calling emergency services.

Finally, the location of the operation matters more for these patients than for most. An accredited surgical facility with an anesthesiologist who reviews the medication plan before the day of surgery, and with a way to return a bleeding patient to the operating room quickly, is part of what makes a planned pause reasonable.

The honest summary

Blood thinners before cosmetic surgery are not a paperwork item. They are prescribed to prevent strokes, clots, and stent closures, and pausing them for an elective operation means borrowing against that protection. For many patients on apixaban, rivaroxaban, or warfarin for lower-risk atrial fibrillation or an old provoked clot, a short, planned pause is routine and well studied: about two days off a DOAC before a high-bleeding-risk operation, about five days off warfarin with an INR check, and no bridging injections, which a large trial showed added bleeding without preventing strokes.

For other patients the honest answer is to wait. A clot in the past three months, a recent stroke or heart attack, a mechanical heart valve, and a coronary stent still within its dual antiplatelet window are all reasons an elective cosmetic operation should be postponed or reconsidered, and no surgeon should talk around a prescriber who says so. For small treatments, injectables and minor skin procedures, the more sensible plan is usually to keep the prescribed thinner and accept the bruising.

The common thread is who makes the decision. The surgeon knows the bleeding risk of the operation. The cardiologist or hematologist knows the clotting risk of stopping. A safe plan requires both, written down before the date is set, covering when to stop, whether anything replaces the drug, and exactly when it restarts. A patient who never hears their prescriber's name mentioned in the surgical office should ask why.